Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ALDX Stock Alerts

Aldeyra Therapeutics (ALDX) Financials

Aldeyra Therapeutics logo
$2.13 -0.17 (-7.17%)
As of 01:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Aldeyra Therapeutics

Annual Income Statements for Aldeyra Therapeutics

This table shows Aldeyra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Consolidated Net Income / (Loss)		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Net Income / (Loss) Continuing Operations		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Total Pre-Tax Income 		-12 -19 -22 -39 -62 -38 -58 -62 -38 -56 -34
Total Operating Income		 -12 -19 -22 -40 -63 -36 -56 -63 -43 -60 -35
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 19 22 40 63 36 56 63 43 60 35
Selling, General & Admin Expense		 4.41 5.52 6.19 9.88 12 9.99 11 15 13 12 9.60
Research & Development Expense		 7.57 13 16 30 51 26 45 47 29 48 26
Total Other Income / (Expense), net		 -0.10 -0.00 0.15 0.81 0.94 -1.61 -1.56 0.66 5.25 4.27 1.42
Interest Expense		 0.11 0.11 0.11 0.15 0.60 1.90 1.74 1.69 2.07 1.93 1.91
Interest & Investment Income		 0.01 0.10 0.26 0.95 1.54 0.29 0.19 2.35 7.32 6.19 3.32
Basic Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Weighted Average Basic Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.41M 58.94M 59.48M 60.06M
Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Weighted Average Diluted Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.41M 58.94M 59.48M 60.06M
Weighted Average Basic & Diluted Shares Outstanding		 8.63M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.58M 58.90M 59.71M 60.18M

Quarterly Income Statements for Aldeyra Therapeutics

This table shows Aldeyra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Consolidated Net Income / (Loss)		 -8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Net Income / (Loss) Continuing Operations		 -8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Total Pre-Tax Income 		-8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Total Operating Income		 -9.55 -6.10 -9.39 -18 -16 -17 -10 -10 -8.00 -6.67 -3.55
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.55 6.10 9.39 18 16 17 10 10 8.00 6.67 3.55
Selling, General & Admin Expense		 2.59 1.80 3.21 3.04 3.70 1.95 3.00 1.66 2.57 2.36 1.14
Research & Development Expense		 6.96 4.30 6.18 15 12 15 7.42 8.51 5.43 4.30 2.41
Total Other Income / (Expense), net		 1.36 1.34 1.31 1.16 1.02 0.77 0.50 0.40 0.31 0.21 0.09
Interest Expense		 0.54 0.51 0.50 0.48 0.48 0.47 0.48 0.47 0.48 0.48 0.47
Interest & Investment Income		 1.90 1.86 1.81 1.64 1.50 1.24 0.98 0.87 0.79 0.68 0.56
Basic Earnings per Share		 ($0.14) ($0.08) ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06)
Weighted Average Basic Shares Outstanding		 58.99M 58.94M 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M
Diluted Earnings per Share		 ($0.14) ($0.08) ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06)
Weighted Average Diluted Shares Outstanding		 58.99M 58.94M 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M
Weighted Average Basic & Diluted Shares Outstanding		 58.82M 58.90M 59.41M 59.42M 59.55M 59.71M 59.90M 59.90M 60.16M 60.18M 60.32M

Annual Cash Flow Statements for Aldeyra Therapeutics

This table details how cash moves in and out of Aldeyra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.12 -2.63 8.01 27 -2.93 33 152 -85 -1.60 -88 16
Net Cash From Operating Activities		 -9.31 -15 -19 -30 -45 -37 -43 -57 -30 -43 -33
Net Cash From Continuing Operating Activities		 -9.31 -15 -19 -30 -45 -37 -43 -57 -30 -43 -33
Net Income / (Loss) Continuing Operations		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Consolidated Net Income / (Loss)		 -12 -19 -22 -39 -61 -38 -58 -62 -38 -56 -34
Depreciation Expense		 0.02 0.04 0.04 0.07 0.10 0.06 0.26 0.26 0.26 0.25 0.25
Amortization Expense		 0.04 0.29 0.15 -0.18 -0.34 0.47 0.41 0.28 0.34 -1.49 -0.93
Non-Cash Adjustments To Reconcile Net Income		 2.19 2.76 2.71 4.14 15 8.84 7.11 8.29 5.75 7.97 6.36
Changes in Operating Assets and Liabilities, net		 0.54 0.46 0.22 5.00 1.43 -9.31 7.44 -3.44 0.86 5.91 -5.18
Net Cash From Investing Activities		 -13 -0.23 -10 -23 18 29 -0.01 -30 30 -45 48
Net Cash From Continuing Investing Activities		 -13 -0.23 -10 -23 18 29 -0.01 -30 30 -45 48
Purchase of Investments		 -13 -16 -35 -60 -58 -5.78 0.00 -93 0.00 -97 -40
Sale and/or Maturity of Investments		 0.00 16 25 37 76 35 0.00 63 30 52 88
Net Cash From Financing Activities		 28 13 37 81 24 42 194 1.22 -1.27 -0.17 1.12
Net Cash From Continuing Financing Activities		 28 13 37 81 24 42 194 1.22 -1.27 -0.17 1.12
Repayment of Debt		 - - 0.00 -1.40 -0.12 - - 0.00 -1.04 -0.29 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 -0.27 0.00
Issuance of Common Equity		 - 13 38 82 8.09 41 190 0.10 0.11 0.04 0.02
Other Financing Activities, net		 28 0.00 -0.17 - 1.16 1.06 4.62 1.12 -0.34 0.35 1.10
Cash Interest Paid		 0.07 0.08 0.09 0.09 0.24 1.39 1.34 1.34 1.70 1.75 1.69

Quarterly Cash Flow Statements for Aldeyra Therapeutics

This table details how cash moves in and out of Aldeyra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -8.34 -0.51 -40 -31 -2.91 -14 -4.18 -9.11 18 11 -5.04
Net Cash From Operating Activities		 -8.02 0.50 -9.97 -13 -7.97 -12 -12 -8.56 -7.02 -5.30 -5.11
Net Cash From Continuing Operating Activities		 -8.02 0.50 -9.97 -13 -7.97 -12 -12 -8.56 -7.02 -5.30 -5.11
Net Income / (Loss) Continuing Operations		 -8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Consolidated Net Income / (Loss)		 -8.19 -4.75 -8.08 -17 -15 -16 -9.93 -9.77 -7.69 -6.46 -3.45
Depreciation Expense		 0.06 0.07 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.07
Amortization Expense		 0.10 0.07 -0.11 -0.49 -0.47 -0.42 -0.34 -0.38 -0.22 0.01 0.05
Non-Cash Adjustments To Reconcile Net Income		 0.79 -0.80 1.55 1.94 3.23 1.26 2.49 0.20 2.58 1.09 -0.99
Changes in Operating Assets and Liabilities, net		 -0.79 5.92 -3.39 2.11 4.32 2.87 -4.75 1.33 -1.76 0.00 -0.79
Net Cash From Investing Activities		 - - -30 -18 5.26 -1.56 7.29 -0.55 25 16 0.00
Net Cash From Continuing Investing Activities		 - - -30 -18 5.26 -1.56 7.29 -0.55 25 16 0.00
Purchase of Investments		 - - -30 -30 -15 -22 -16 -25 - - 0.00
Sale and/or Maturity of Investments		 - - 0.00 12 20 20 23 24 25 16 0.00
Net Cash From Financing Activities		 -0.32 -1.01 0.02 - -0.20 0.01 1.00 - 0.12 - 0.07
Net Cash From Continuing Financing Activities		 -0.32 -1.01 0.02 - -0.20 0.01 1.00 - 0.12 - 0.07
Issuance of Common Equity		 0.06 - 0.02 - -0.20 0.22 0.02 - - - 0.00
Other Financing Activities, net		 -0.37 0.03 0.00 - - 0.35 0.98 - 0.12 - 0.07
Cash Interest Paid		 0.44 0.44 0.44 0.44 0.44 0.42 0.42 0.43 0.43 0.42 0.42

Annual Balance Sheets for Aldeyra Therapeutics

This table presents Aldeyra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 28 25 44 95 76 83 233 181 148 105 72
Total Current Assets		 28 25 44 95 75 83 233 181 148 104 72
Cash & Equivalents		 15 12 20 47 44 78 230 144 143 55 70
Prepaid Expenses		 0.50 0.22 1.02 1.17 1.80 5.20 2.96 6.72 4.99 2.92 1.74
Plant, Property, & Equipment, net		 0.08 0.06 0.04 0.24 0.15 0.06 0.03 0.02 0.01 0.00 0.00
Total Noncurrent Assets		 0.04 0.00 0.17 0.09 0.20 0.23 0.35 0.25 0.51 0.53 0.28
Other Noncurrent Operating Assets		 0.04 0.00 0.17 0.09 0.20 0.23 0.35 0.25 0.51 0.53 0.28
Total Liabilities & Shareholders' Equity		 28 25 44 95 76 83 233 181 148 105 72
Total Liabilities		 3.33 3.54 4.57 8.47 27 24 27 30 29 34 28
Total Current Liabilities		 2.12 2.30 3.35 8.47 13 12 12 15 22 19 28
Short-Term Debt		 0.08 0.08 0.12 - 0.00 3.66 0.00 0.91 15 0.03 15
Accounts Payable		 0.85 0.28 1.00 3.05 0.81 0.38 1.02 0.13 1.34 0.18 0.16
Accrued Expenses		 1.19 1.95 2.24 5.42 12 8.13 11 14 5.54 12 6.12
Current Deferred Revenue		 - - - - - - - - 0.00 6.00 6.00
Other Current Liabilities		 - - - - 0.23 0.23 0.23 0.25 0.24 0.27 0.28
Total Noncurrent Liabilities		 1.21 1.24 1.22 0.00 15 11 16 15 6.27 15 0.00
Long-Term Debt		 1.21 1.24 1.22 - 15 11 16 15 0.00 15 0.00
Other Noncurrent Operating Liabilities		 - - - - - 0.00 0.13 0.00 6.27 - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 25 22 40 87 48 60 206 151 120 71 44
Total Preferred & Common Equity		 25 22 40 87 48 60 206 151 120 71 44
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 25 22 40 87 48 60 206 151 120 71 44
Common Stock		 83 99 139 225 247 296 500 508 514 521 528
Retained Earnings		 -59 -77 -100 -139 -199 -237 -295 -357 -394 -450 -484
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.00 -0.02 -0.01 0.01 0.00 0.00 -0.10 0.00 0.04 0.00

Quarterly Balance Sheets for Aldeyra Therapeutics

This table presents Aldeyra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 147 141 126 117 93 85 78 66
Total Current Assets		 147 141 126 117 93 85 77 66
Cash & Equivalents		 143 102 71 68 50 41 59 65
Prepaid Expenses		 3.88 7.81 5.32 3.98 2.67 2.64 2.16 1.27
Plant, Property, & Equipment, net		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.06 0.45 0.39 0.60 0.47 0.40 0.34 0.21
Other Noncurrent Operating Assets		 0.06 0.45 0.39 0.60 0.47 0.40 0.34 0.21
Total Liabilities & Shareholders' Equity		 147 141 126 117 93 85 78 66
Total Liabilities		 24 28 28 32 30 30 29 24
Total Current Liabilities		 22 22 28 17 14 30 28 24
Short-Term Debt		 13 15 15 0.28 0.00 15 15 15
Accounts Payable		 0.25 0.28 0.25 0.19 0.35 1.46 0.01 0.14
Accrued Expenses		 7.84 5.94 5.84 10 7.68 6.66 7.00 2.67
Current Deferred Revenue		 - - 6.00 6.00 6.00 6.00 6.00 6.00
Other Current Liabilities		 0.07 0.25 0.26 0.26 0.26 0.26 0.27 0.21
Total Noncurrent Liabilities		 2.66 6.21 0.14 15 15 0.14 0.07 0.00
Long-Term Debt		 2.66 0.00 - 15 15 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 - 6.21 0.14 0.07 0.21 0.14 0.07 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 123 113 98 85 64 55 49 42
Total Preferred & Common Equity		 123 113 98 85 64 55 49 42
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 123 113 98 85 64 55 49 42
Common Stock		 513 516 518 519 524 525 527 530
Retained Earnings		 -390 -402 -419 -434 -460 -470 -477 -487
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.00 -0.01 0.07 0.00 -0.01 0.00 0.00

Annual Metrics And Ratios for Aldeyra Therapeutics

This table displays calculated financial ratios and metrics derived from Aldeyra Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 9,712,521.00 12,576,326.00 19,117,676.00 26,244,434.00 27,952,937.00 38,820,347.00 58,092,105.00 58,560,078.00 58,822,083.00 - 60,162,773.00
DEI Adjusted Shares Outstanding		 9,712,521.00 12,576,326.00 19,117,676.00 26,244,434.00 27,952,937.00 38,820,347.00 58,092,105.00 58,560,078.00 58,822,083.00 - 60,162,773.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.24 -1.49 -1.17 -1.48 -2.18 -0.97 -0.99 -1.06 -0.64 - -0.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -149.09% -53.90% -21.42% -78.50% -59.05% 43.31% -54.77% -11.87% 32.10% -45.43% 41.42%
EBIT Growth		 -142.54% -55.94% -20.28% -76.53% -58.88% 42.26% -54.36% -11.49% 31.73% -40.48% 41.34%
NOPAT Growth		 -64.90% -55.94% -20.28% -76.53% -58.88% 42.26% -54.36% -11.49% 31.73% -40.48% 41.34%
Net Income Growth		 -133.08% -54.67% -19.47% -74.09% -56.39% 38.26% -53.85% -7.35% 39.47% -48.77% 39.40%
EPS Growth		 54.69% -17.86% 15.15% -27.86% -25.14% 50.45% 3.60% 0.93% 39.62% -46.88% 40.43%
Operating Cash Flow Growth		 -94.97% -62.67% -26.90% -55.32% -50.66% 16.65% -13.50% -33.09% 46.46% -42.48% 22.83%
Free Cash Flow Firm Growth		 0.43% -57.86% -24.80% -45.52% -76.97% 18.29% -3.23% -32.04% 34.33% -18.00% 16.04%
Invested Capital Growth		 -43.75% -36.75% -3.22% -247.48% -54.03% 69.73% -162.68% 12.79% -5.68% -91.78% 30.26%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.23% -1.29% -51.79% 2.42% -4.22% 6.35% -7.66% 2.65% 15.28% -21.78% 22.34%
EBIT Q/Q Growth		 -19.16% -1.72% -49.91% 2.57% -2.94% 4.23% -7.90% 2.65% 15.08% -21.11% 21.94%
NOPAT Q/Q Growth		 -19.16% -1.72% -49.91% 2.57% -2.94% 4.23% -7.90% 2.65% 15.08% -21.11% 21.94%
Net Income Q/Q Growth		 -18.78% -1.62% -49.44% 3.50% -4.34% 5.89% -9.36% 4.40% 17.84% -24.68% 21.64%
EPS Q/Q Growth		 -172.54% 6.25% -37.25% 16.36% -4.67% 14.62% 1.83% 4.50% 17.95% -25.33% 23.29%
Operating Cash Flow Q/Q Growth		 -17.67% -6.35% -6.12% -10.96% -7.81% 7.20% -8.30% 0.61% 27.89% -40.88% 16.81%
Free Cash Flow Firm Q/Q Growth		 -13.08% -8.19% -33.77% 4.92% -8.59% 6.99% -5.62% -2.28% 23.19% -31.08% 11.70%
Invested Capital Q/Q Growth		 -121.75% -2.77% -197.97% -34.28% 1.39% -58.63% -36.22% -1.01% -87.26% -22.21% 2.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 97.89% 98.74% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.84% 100.02% 99.34% 97.97% 98.51% 104.43% 102.77% 98.95% 87.73% 92.90% 95.98%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.60% -80.38% -72.95% -61.63% -90.31% -69.81% -43.56% -34.77% -27.73% -58.54% -58.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.60% -80.38% -72.95% -61.63% -90.31% -69.81% -43.56% -34.77% -27.73% -58.54% -58.73%
Return on Equity Simple (ROE_SIMPLE)		 -48.60% -86.37% -56.41% -44.90% -126.51% -63.11% -28.08% -41.07% -31.34% -78.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.39 -13 -16 -28 -44 -25 -39 -44 -30 -42 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.03% -22.49% -20.24% -16.42% -21.88% -19.83% -13.30% -9.74% -5.30% -12.88% -13.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -22.20% -48.91% -41.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -12 -19 -22 -40 -63 -36 -56 -63 -43 -60 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -18 -22 -40 -63 -36 -56 -62 -42 -61 -36
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.65 3.11 3.28 2.51 3.38 4.48 1.13 2.70 1.72 4.19 7.04
Price to Tangible Book Value (P/TBV)		 2.65 3.11 3.28 2.51 3.38 4.48 1.13 2.70 1.72 4.19 7.04
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.06 0.03 0.00 0.30 0.25 0.08 0.10 0.13 0.21 0.34
Long-Term Debt to Equity		 0.05 0.06 0.03 0.00 0.30 0.19 0.08 0.10 0.00 0.21 0.00
Financial Leverage		 -1.08 -1.07 -1.06 -1.07 -1.13 -1.13 -1.04 -1.04 -1.06 -1.12 -1.22
Leverage Ratio		 1.19 1.15 1.13 1.10 1.27 1.48 1.19 1.16 1.22 1.33 1.53
Compound Leverage Factor		 1.20 1.15 1.13 1.08 1.25 1.54 1.23 1.15 1.07 1.23 1.47
Debt to Total Capital		 4.93% 5.73% 3.26% 0.00% 23.20% 20.23% 7.01% 9.49% 11.22% 17.47% 25.63%
Short-Term Debt to Total Capital		 0.30% 0.34% 0.28% 0.00% 0.00% 4.91% 0.00% 0.55% 11.22% 0.04% 25.63%
Long-Term Debt to Total Capital		 4.63% 5.39% 2.98% 0.00% 23.20% 15.33% 7.01% 8.94% 0.00% 17.43% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.07% 94.27% 96.74% 100.00% 76.80% 79.77% 92.99% 90.51% 88.78% 82.53% 74.37%
Debt to EBITDA		 -0.11 -0.07 -0.06 0.00 -0.23 -0.42 -0.28 -0.25 -0.36 -0.25 -0.42
Net Debt to EBITDA		 2.20 1.28 1.87 0.00 0.93 1.75 3.86 2.55 3.03 1.40 1.52
Long-Term Debt to EBITDA		 -0.10 -0.07 -0.05 0.00 -0.23 -0.32 -0.28 -0.24 0.00 -0.24 0.00
Debt to NOPAT		 -0.15 -0.10 -0.08 0.00 -0.33 -0.59 -0.39 -0.36 -0.51 -0.36 -0.62
Net Debt to NOPAT		 3.13 1.80 2.64 0.00 1.33 2.46 5.45 3.61 4.26 2.05 2.22
Long-Term Debt to NOPAT		 -0.14 -0.09 -0.08 0.00 -0.33 -0.45 -0.39 -0.34 0.00 -0.36 0.00
Altman Z-Score		 8.67 5.75 13.32 13.10 -1.91 2.30 3.66 5.28 0.68 -1.63 -3.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.28 10.93 13.11 11.18 5.82 6.69 19.77 11.78 6.64 5.59 2.58
Quick Ratio		 13.04 10.84 12.81 11.05 5.68 6.27 19.52 11.35 6.42 5.44 2.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.96 -13 -16 -23 -40 -33 -34 -45 -30 -35 -29
Operating Cash Flow to CapEx		 -10,812.66% -128,260.05% -77,639.90% -11,353.99% -472,077.09% 0.00% -545,169.19% -347,105.39% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -70.87 -119.08 -138.20 -155.44 -66.87 -17.33 -19.55 -26.55 -14.26 -18.09 -15.36
Operating Cash Flow to Interest Expense		 -82.91 -143.57 -169.43 -203.40 -74.50 -19.69 -24.43 -33.43 -14.64 -22.43 -17.50
Operating Cash Flow Less CapEx to Interest Expense		 -83.68 -143.68 -169.65 -205.19 -74.51 -19.69 -24.43 -33.44 -14.64 -22.43 -17.50
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.42 -1.95 -2.01 -6.98 -11 -3.26 -8.55 -7.46 -7.88 -15 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.43 -0.52 -0.06 -4.97 -3.77 7.50 -5.30 1.09 -0.42 -7.23 4.57
Enterprise Value (EV)		 40 44 88 124 104 204 18 249 79 211 257
Market Capitalization		 66 67 130 218 162 266 232 408 206 297 312
Book Value per Share		 $2.56 $1.72 $2.07 $3.30 $1.72 $1.53 $3.54 $2.58 $2.04 $1.19 $0.74
Tangible Book Value per Share		 $2.56 $1.72 $2.07 $3.30 $1.72 $1.53 $3.54 $2.58 $2.04 $1.19 $0.74
Total Capital		 26 23 41 87 63 75 221 167 135 86 60
Total Debt		 1.29 1.32 1.34 0.00 15 15 16 16 15 15 15
Total Long-Term Debt		 1.21 1.24 1.22 0.00 15 11 16 15 0.00 15 0.00
Net Debt		 -26 -24 -42 -94 -59 -63 -214 -158 -128 -86 -55
Capital Expenditures (CapEx)		 0.09 0.01 0.02 0.26 0.01 0.00 0.01 0.02 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.54 -2.00 -2.22 -7.30 -11 -3.55 -8.81 -7.73 -2.13 -16 -11
Debt-free Net Working Capital (DFNWC)		 26 23 41 86 62 74 221 167 141 86 59
Net Working Capital (NWC)		 26 23 41 86 62 71 221 166 126 85 44
Net Nonoperating Expense (NNE)		 3.70 5.61 6.60 11 17 12 18 18 7.59 14 9.16
Net Nonoperating Obligations (NNO)		 -26 -24 -42 -94 -59 -63 -214 -158 -128 -86 -55
Total Depreciation and Amortization (D&A)		 0.05 0.33 0.19 -0.11 -0.24 0.53 0.67 0.54 0.60 -1.24 -0.68
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 8.63M 15.13M 19.66M 27.40M 29.66M 47.25M 58.10M 58.41M 58.94M 59.48M 60.06M
Adjusted Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) ($1.06) ($0.64) ($0.94) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 8.63M 15.13M 19.66M 27.40M 29.66M 47.25M 58.10M 58.41M 58.94M 59.48M 60.06M
Adjusted Basic & Diluted Earnings per Share		 ($1.40) ($1.65) ($1.40) ($1.79) ($2.24) ($1.11) ($1.07) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.71M 11.35M 15.92M 21.69M 27.11M 33.97M 54.04M 58.58M 58.90M 59.71M 60.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.39 -13 -16 -28 -44 -25 -39 -44 -30 -42 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -106.75 -177.20 -198.22 -270.44 -104.45 -19.13 -32.27 -37.00 -20.66 -31.21 -18.51
NOPAT to Interest Expense		 -74.73 -124.04 -138.75 -189.31 -73.12 -13.39 -22.59 -25.90 -14.46 -21.85 -12.96
EBIT Less CapEx to Interest Expense		 -107.52 -177.31 -198.44 -272.24 -104.47 -19.13 -32.28 -37.01 -20.66 -31.21 -18.51
NOPAT Less CapEx to Interest Expense		 -75.49 -124.15 -138.97 -191.10 -73.13 -13.39 -22.59 -25.91 -14.46 -21.85 -12.96
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.48% 0.00%

Quarterly Metrics And Ratios for Aldeyra Therapeutics

This table displays calculated financial ratios and metrics derived from Aldeyra Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 58,595,850.00 58,822,083.00 58,895,768.00 59,414,489.00 59,421,551.00 - 59,708,654.00 59,895,588.00 59,895,588.00 60,162,773.00 60,182,782.00
DEI Adjusted Shares Outstanding		 58,595,850.00 58,822,083.00 58,895,768.00 59,414,489.00 59,421,551.00 - 59,708,654.00 59,895,588.00 59,895,588.00 60,162,773.00 60,182,782.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.14 -0.08 -0.14 -0.28 -0.25 - -0.17 -0.16 -0.13 -0.11 -0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 35.93% 56.07% 43.31% -81.11% -76.22% -184.11% -13.36% 43.12% 50.72% 61.05% 67.97%
EBIT Growth		 35.40% 55.48% 44.10% -74.11% -68.97% -171.87% -11.00% 43.53% 50.42% 59.78% 65.98%
NOPAT Growth		 35.40% 55.48% 44.10% -74.11% -68.97% -171.87% -11.00% 43.53% 50.42% 59.78% 65.98%
Net Income Growth		 43.75% 63.16% 48.24% -87.47% -84.60% -232.61% -22.86% 42.03% 49.13% 59.13% 65.23%
EPS Growth		 44.00% 63.64% 48.15% -86.67% -78.57% -237.50% -21.43% 42.86% 48.00% 62.96% 64.71%
Operating Cash Flow Growth		 36.18% 104.46% -5.60% 1.00% 0.62% -2,505.25% -25.04% 35.31% 11.96% 55.97% 59.02%
Free Cash Flow Firm Growth		 -6.67% 64.00% -33.70% -37.06% 68.19% -13.68% 97.49% 79.18% -126.86% -111.43% -1,692.03%
Invested Capital Growth		 43.00% -5.68% 62.80% -17.49% -193.87% -91.78% -157.43% -69.38% 12.25% 30.26% 33.58%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.75% 36.52% -58.49% -95.13% 10.24% -2.35% 36.76% 2.09% 22.24% 19.10% 48.00%
EBIT Q/Q Growth		 7.66% 36.15% -54.05% -91.70% 10.39% -2.73% 37.10% 2.48% 21.32% 16.66% 46.81%
NOPAT Q/Q Growth		 7.66% 36.15% -54.05% -91.70% 10.39% -2.73% 37.10% 2.48% 21.32% 16.66% 46.81%
Net Income Q/Q Growth		 8.90% 41.94% -70.04% -108.45% 10.30% -4.60% 37.19% 1.63% 21.29% 15.96% 46.57%
EPS Q/Q Growth		 6.67% 42.86% -75.00% -100.00% 10.71% -8.00% 37.04% 5.88% 18.75% 23.08% 40.00%
Operating Cash Flow Q/Q Growth		 39.92% 106.24% -2,092.78% -32.61% 39.70% -50.93% -3.60% 31.39% 17.93% 24.53% 3.57%
Free Cash Flow Firm Q/Q Growth		 -16.54% 61.00% -264.77% 17.32% 72.95% -39.35% 91.96% -587.00% -194.71% -29.87% 31.85%
Invested Capital Q/Q Growth		 27.06% -87.26% 44.01% -53.61% -82.45% -22.21% 24.84% -1.07% 5.48% 2.88% 28.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 85.72% 77.95% 86.04% 93.56% 93.65% 95.36% 95.22% 96.05% 96.09% 96.90% 97.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.04% -27.73% -23.94% -33.19% -43.05% -58.54% -65.19% -65.91% -64.31% -58.73% -51.76%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.04% -27.73% -23.94% -33.19% -43.05% -58.54% -65.19% -65.91% -64.31% -58.73% -51.76%
Return on Equity Simple (ROE_SIMPLE)		 -37.15% 0.00% -26.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.69 -4.27 -6.58 -13 -11 -12 -7.30 -7.12 -5.60 -4.67 -2.48
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.01% -0.34% -1.13% -3.52% -3.40% -3.93% -2.73% -3.08% -2.65% -2.55% -1.56%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.16% -5.11% -11.10% -11.25% -13.49% -9.28% -10.11% -8.69% -7.84% -4.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.55 -6.10 -9.39 -18 -16 -17 -10 -10 -8.00 -6.67 -3.55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.39 -5.96 -9.45 -18 -17 -17 -11 -10 -8.15 -6.60 -3.43
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.18 1.72 1.70 2.00 3.76 4.19 5.40 4.15 6.35 7.04 2.41
Price to Tangible Book Value (P/TBV)		 3.18 1.72 1.70 2.00 3.76 4.19 5.40 4.15 6.35 7.04 2.41
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.13 0.13 0.13 0.16 0.18 0.21 0.24 0.27 0.31 0.34 0.36
Long-Term Debt to Equity		 0.02 0.00 0.00 0.00 0.18 0.21 0.24 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.06 -1.06 -1.06 -1.08 -1.12 -1.09 -1.12 -1.17 -1.22 -1.18
Leverage Ratio		 1.18 1.22 1.23 1.23 1.27 1.33 1.32 1.37 1.45 1.53 1.51
Compound Leverage Factor		 1.01 0.95 1.06 1.15 1.19 1.26 1.26 1.32 1.40 1.49 1.47
Debt to Total Capital		 11.59% 11.22% 11.82% 13.42% 15.22% 17.47% 19.19% 21.51% 23.59% 25.63% 26.63%
Short-Term Debt to Total Capital		 9.68% 11.22% 11.82% 13.42% 0.28% 0.04% 0.00% 21.51% 23.59% 25.63% 26.63%
Long-Term Debt to Total Capital		 1.91% 0.00% 0.00% 0.00% 14.94% 17.43% 19.19% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 88.41% 88.78% 88.18% 86.58% 84.78% 82.53% 80.81% 78.49% 76.41% 74.37% 73.37%
Debt to EBITDA		 -0.32 -0.36 -0.43 -0.35 -0.30 -0.25 -0.24 -0.28 -0.33 -0.42 -0.53
Net Debt to EBITDA		 2.55 3.03 3.37 2.43 1.93 1.40 1.20 1.22 1.30 1.52 1.73
Long-Term Debt to EBITDA		 -0.05 0.00 0.00 0.00 -0.30 -0.24 -0.24 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.46 -0.51 -0.61 -0.51 -0.44 -0.36 -0.35 -0.41 -0.48 -0.62 -0.77
Net Debt to NOPAT		 3.61 4.26 4.76 3.49 2.81 2.05 1.75 1.79 1.90 2.22 2.50
Long-Term Debt to NOPAT		 -0.08 0.00 0.00 0.00 -0.43 -0.36 -0.35 0.00 0.00 0.00 0.00
Altman Z-Score		 6.78 1.50 0.95 0.06 1.35 -0.26 0.69 -2.72 -1.61 -2.25 -7.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.81 6.64 6.50 4.55 6.80 5.59 6.49 2.86 2.72 2.58 2.72
Quick Ratio		 6.63 6.42 6.14 4.36 6.57 5.44 6.30 2.77 2.64 2.52 2.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.86 -3.85 -14 -12 -3.14 -4.37 -0.35 -2.41 -7.12 -9.24 -6.30
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -18.30 -7.48 -28.13 -24.28 -6.54 -9.28 -0.73 -5.13 -14.95 -19.44 -13.44
Operating Cash Flow to Interest Expense		 -14.90 0.97 -20.00 -27.69 -16.64 -25.56 -25.79 -18.18 -14.75 -11.15 -10.90
Operating Cash Flow Less CapEx to Interest Expense		 -14.90 0.97 -20.00 -27.69 -16.64 -25.56 -25.79 -18.18 -14.75 -11.15 -10.90
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.21 -7.88 -4.41 -6.78 -12 -15 -11 -11 -11 -11 -7.55
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.17 -0.42 7.45 -1.01 -8.16 -7.23 -6.95 -4.70 1.52 4.57 3.82
Enterprise Value (EV)		 264 79 75 92 223 211 268 163 253 257 52
Market Capitalization		 391 206 193 197 320 297 343 229 313 312 102
Book Value per Share		 $2.10 $2.04 $1.93 $1.65 $1.43 $1.19 $1.06 $0.92 $0.82 $0.74 $0.70
Tangible Book Value per Share		 $2.10 $2.04 $1.93 $1.65 $1.43 $1.19 $1.06 $0.92 $0.82 $0.74 $0.70
Total Capital		 139 135 129 114 100 86 79 70 64 60 57
Total Debt		 16 15 15 15 15 15 15 15 15 15 15
Total Long-Term Debt		 2.66 0.00 0.00 0.00 15 15 15 0.00 0.00 0.00 0.00
Net Debt		 -127 -128 -118 -105 -97 -86 -75 -67 -60 -55 -50
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.28 -2.13 1.34 -7.03 -13 -16 -12 -12 -11 -11 -7.75
Debt-free Net Working Capital (DFNWC)		 139 141 134 113 100 86 78 70 64 59 57
Net Working Capital (NWC)		 126 126 119 98 100 85 78 55 49 44 42
Net Nonoperating Expense (NNE)		 1.50 0.48 1.51 4.24 3.82 4.20 2.63 2.65 2.09 1.79 0.97
Net Nonoperating Obligations (NNO)		 -127 -128 -118 -105 -97 -86 -75 -67 -60 -55 -50
Total Depreciation and Amortization (D&A)		 0.16 0.14 -0.05 -0.43 -0.41 -0.36 -0.28 -0.32 -0.15 0.07 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.14) ($0.08) ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 58.99M 58.94M 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M
Adjusted Diluted Earnings per Share		 ($0.14) ($0.08) ($0.14) ($0.28) ($0.25) ($0.27) ($0.17) ($0.16) ($0.13) ($0.10) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 58.99M 58.94M 59.41M 59.41M 59.53M 59.48M 59.89M 60.05M 60.13M 60.06M 60.32M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.82M 58.90M 59.41M 59.42M 59.55M 59.71M 59.90M 59.90M 60.16M 60.18M 60.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.69 -4.27 -6.58 -13 -11 -12 -7.30 -7.12 -5.60 -4.67 -2.48
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -17.73 -11.86 -18.84 -37.70 -33.67 -35.21 -21.57 -21.61 -16.81 -14.03 -7.57
NOPAT to Interest Expense		 -12.41 -8.30 -13.19 -26.39 -23.57 -24.65 -15.10 -15.13 -11.77 -9.82 -5.30
EBIT Less CapEx to Interest Expense		 -17.73 -11.86 -18.84 -37.70 -33.67 -35.21 -21.57 -21.61 -16.81 -14.03 -7.57
NOPAT Less CapEx to Interest Expense		 -12.41 -8.30 -13.19 -26.39 -23.57 -24.65 -15.10 -15.13 -11.77 -9.82 -5.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.48% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Aldeyra Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aldeyra Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Aldeyra Therapeutics' net income appears to be on an upward trend, with a most recent value of -$33.85 million in 2025, rising from -$12.09 million in 2015. The previous period was -$55.85 million in 2024. Find out what analysts predict for Aldeyra Therapeutics in the coming months.

Aldeyra Therapeutics' total operating income in 2025 was -$35.27 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $35.27 million

Over the last 10 years, Aldeyra Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Aldeyra Therapeutics' total liabilities were at $27.81 million at the end of 2025, a 17.2% decrease from 2024, and a 736.0% increase since 2015.

In the past 10 years, Aldeyra Therapeutics' cash and equivalents has ranged from $12.02 million in 2016 to $229.79 million in 2021, and is currently $70.04 million as of their latest financial filing in 2025.

Over the last 10 years, Aldeyra Therapeutics' book value per share changed from 2.56 in 2015 to 0.74 in 2025, a change of -71.3%.


Related Companies

Financial statements for NASDAQ:ALDX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The window is closing
We printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...
American Alternative | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel